Peter Ginsberg heads business development for United Therapeutics (UT).  His focus is on acquiring and in-licensing promising drug candidates to expand UT’s pipeline, with an emphasis on orphan oncology and pulmonary indications.  Prior to UT, Ginsberg was VP of Business & Technology Development for the North Carolina Biotechnology Center, where his group financed and advised emerging biotechnology companies.  He also consulted to a range of biopharma companies on BD transactions and strategic opportunities.

                

Previously, Ginsberg headed business development and strategic planning for SurModics, a publicly traded leader in the field of drug delivery.  He also spent 15 years in the healthcare investment industry, during which time he was named a Wall Street Journal All-Star as Piper Jaffray’s lead biotechnology analyst.

Ginsberg acts as a reviewer for the National Cancer Institute and the National Heart, Lung and Blood Institute.  He earned an A.B. cum laude in Economics from Princeton University and an M.B.A. from the Tuck School of Business at Dartmouth College, where he was a Tuck Scholar.